Trial Profile

A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vunakizumab (Primary)
Indications Plaque psoriasis
Focus Registrational; Therapeutic Use
Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

27 Aug 2024 Results published in the Media Release
27 Aug 2024 According to a China National Medical Products Administration media release, in February 2023 results from this trial were presented.
27 Aug 2024 Status changed to completed, according to a China National Medical Products Administration media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com